MX2022016005A - Anticuerpos de fijacion a protofibrillas de \03b1-sinucleina. - Google Patents

Anticuerpos de fijacion a protofibrillas de \03b1-sinucleina.

Info

Publication number
MX2022016005A
MX2022016005A MX2022016005A MX2022016005A MX2022016005A MX 2022016005 A MX2022016005 A MX 2022016005A MX 2022016005 A MX2022016005 A MX 2022016005A MX 2022016005 A MX2022016005 A MX 2022016005A MX 2022016005 A MX2022016005 A MX 2022016005A
Authority
MX
Mexico
Prior art keywords
binding antibodies
synuclein
ban0805
synuclein protofibril
antibodies
Prior art date
Application number
MX2022016005A
Other languages
English (en)
Inventor
Jessica Sigvardson
Eva Nordström
Patrik Nygren
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of MX2022016005A publication Critical patent/MX2022016005A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se basa, en parte, en el descubrimiento de anticuerpos que se dirigen selectivamente a agregados de a-sinucleína humana tales como oligómeros/protofibrillas, tales como BAN0805. BAN0805 tiene una menor tendencia a fijarse a la diana de a-sinucleína monomérica no deseada en comparación con el anticuerpo monoclonal de ratón mAb47.
MX2022016005A 2020-06-26 2021-06-25 Anticuerpos de fijacion a protofibrillas de \03b1-sinucleina. MX2022016005A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044881P 2020-06-26 2020-06-26
US202063071150P 2020-08-27 2020-08-27
PCT/IB2021/000440 WO2021260434A1 (en) 2020-06-26 2021-06-25 α-SYNUCLEIN PROTOFIBRIL-BINDING ANTIBODIES

Publications (1)

Publication Number Publication Date
MX2022016005A true MX2022016005A (es) 2023-02-02

Family

ID=77627146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016005A MX2022016005A (es) 2020-06-26 2021-06-25 Anticuerpos de fijacion a protofibrillas de \03b1-sinucleina.

Country Status (13)

Country Link
US (2) US11339212B2 (es)
EP (1) EP4172199A1 (es)
JP (2) JP7337959B2 (es)
KR (1) KR20230027095A (es)
CN (1) CN115803341A (es)
AU (1) AU2021298222A1 (es)
CA (1) CA3181207A1 (es)
IL (1) IL298584B2 (es)
MX (1) MX2022016005A (es)
TW (1) TW202212357A (es)
UY (1) UY39295A (es)
WO (1) WO2021260434A1 (es)
ZA (1) ZA202211843B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021298222A1 (en) 2020-06-26 2022-12-15 Bioarctic Ab α-synuclein protofibril-binding antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2255280T3 (es) 1998-07-03 2006-06-16 Innogenetics N.V. Diagnostico diferencial de la neurodegeneracion.
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
US20060018918A1 (en) 2000-12-27 2006-01-26 Board Of Regents, The University Of Texas System Production of stabilized conformational isomers of disease associated proteins
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
WO2005108423A1 (en) 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP1989330A4 (en) 2006-01-31 2009-10-21 Elan Pharm Inc ALPHA-SYNUCLEINE KINASE
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
PT2282758T (pt) 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
CN102317316B (zh) * 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
DK2448968T3 (da) 2009-06-29 2021-04-12 Bioarctic Ab ANTISTOFFER SOM ER SELEKTIVE FOR N-TERMINAL-TRUNKEREDE AMYLOID-ß PROTOFIBRILLER/OLIGOMERER
EP2539366B1 (en) 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
TWI560199B (en) * 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
BR112013033258B1 (pt) * 2011-06-23 2022-09-20 University Of Zurich Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga a alfasinucleína, composição e seus usos
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
CN106661107B (zh) * 2013-12-24 2021-12-24 杨森制药公司 抗vista抗体及片段
US11773166B2 (en) * 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
AU2021298222A1 (en) 2020-06-26 2022-12-15 Bioarctic Ab α-synuclein protofibril-binding antibodies

Also Published As

Publication number Publication date
CA3181207A1 (en) 2021-12-30
UY39295A (es) 2022-01-31
IL298584B2 (en) 2024-10-01
IL298584A (en) 2023-01-01
US11339212B2 (en) 2022-05-24
CN115803341A (zh) 2023-03-14
KR20230027095A (ko) 2023-02-27
AU2021298222A1 (en) 2022-12-15
US20210403542A1 (en) 2021-12-30
JP7337959B2 (ja) 2023-09-04
EP4172199A1 (en) 2023-05-03
JP2023525174A (ja) 2023-06-15
WO2021260434A1 (en) 2021-12-30
ZA202211843B (en) 2024-02-28
JP2023159299A (ja) 2023-10-31
US20230080536A1 (en) 2023-03-16
TW202212357A (zh) 2022-04-01
IL298584B1 (en) 2024-06-01

Similar Documents

Publication Publication Date Title
CU24606B1 (es) Moléculas de anticuerpo que se unen a cd73
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
PH12015502278A1 (en) Novel bispecific binding molecules with antitumoral activity
NZ736535A (en) Antibodies directed against interleukin 36 receptor (il-36r)
PE20141162A1 (es) Anticuerpos anti-il-23
MX2019011986A (es) Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
ATE428731T1 (de) Therapeutische antiköper mit reduzierten nebenwirkungen
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
RS52713B (en) MONGLONAL ANTIBODIES BINDING HGM-CSF AND MEDICAL COMPOSITIONS CONTAINING THE SAME
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
EA201070539A1 (ru) НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ
PE20220708A1 (es) Anticuerpos anti-cd73
MX2018001596A (es) Anticuerpos anti-receptor ccr7 humanizados.
EA202091747A1 (ru) Составы антитела b7-h4
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
MX2020003193A (es) Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos.
PH12021550244A1 (en) Anti-btla antibody
MX2022016005A (es) Anticuerpos de fijacion a protofibrillas de \03b1-sinucleina.
MX2022003465A (es) Anticuerpo monoclonal contra proteína de activación de fibroblasto canino de reacción cruzada con proteína de activación de fibroblasto (fap) de ratón y humana.
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
ZA202205288B (en) Humanized antibody and method for using the same